Clinical Trial Search

Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants

Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 85; 100; 89 percentage of subjects

Primary: Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions. — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 100; 100; 11 percentage of subjects

Primary: Number of Subjects Reporting Any Post Immunization Reactions — 23; 16 participants

Primary: AUC Change in Level of IL-6 — 5.23; 10.17 ug*hour/ml

Primary: Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine — 173; 6; 5 Participants

Primary: Number of Subjects Reporting Any Post Immunization Reactions — 18; 19; 22; 16 participants

Primary: Number of Infants With Adverse Reactions After Vaccination — 22; 24; 17; 7 participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants

Primary: Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration — 1; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium — 0; 0; 0; 0 Participants

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Number of Participants With Moderate-Severe Shigellosis Illness, With Challenge — 14; 17 Participants

Primary: The Etiologies (Bacteria, Viruses, Parasites, Fungi and Others) of Fever Illness Expressed in Percentages of Enrolled Subjects. — 621; 362; 15; 5 Participants

Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants

Primary: Number of Participants With Adverse Events — 9; 5; 8; 10 Participants

Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants

Primary: Cost for the Medical Management of Patients — 581; 661 USD

Primary: Fever >= 100.4 — 7.5; 37.6; 9.5 percentage of participants

Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001

Primary: Number and Percentage of Participants With Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants

Primary: Number of Participants With Shigellosis — 0; 2; 1; 4 Participants

Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius

Primary: Number of Participants With Spontaneous Adverse Events — 17 Participants

Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Primary: Attack Rate of Shigellosis in Vaccinated Subjects. — 13; 18 Participants

Primary: The Proportion of Participants With Shigellosis Following Challenge With Shigella Sonnei 53G Through Day 63 in the Pooled Group of Participants Receiving Two Doses of…

Primary: Percentage of Participants With Clinical and Microbiological Cure: All Participants — 33.8 percentage of participants

Primary: Time to Last Unformed Stool (TLUS) — 37.4; 21.; 68; 46 TLUS (hours)